158342-62-2

Basic information

• Product Name: <3(S),4(S)>-2,4,5-trideoxy-4-<<2-<<<<(1,1-dimethylethoxy)carbonyl>amino>acetyl>amino>-3-methyl-1-oxobutyl>amino>-2,2-difluoro-5-<4-<2-oxo-2-(pentafluorophenoxy)ethoxy>phenyl>-N-(phenylmethyl)-L-glycero-pentonamide
• CAS NO: 158342-62-2
• Molecular Weight: 830.754
• Mol File: 158342-62-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: <3(S),4(S)>-2,4,5-trideoxy-4-<<2-<<<<(1,1-dimethylethoxy)carbonyl>amino>acetyl>amino>-3-methyl-1-oxobutyl>amino>-2,2-difluoro-5-<4-<2-oxo-2-(pentafluorophenoxy)ethoxy>phenyl>-N-(phenylmethyl)-L-glycero-pentonamide(CAS DataBase Reference)
• NIST Chemistry Reference: <3(S),4(S)>-2,4,5-trideoxy-4-<<2-<<<<(1,1-dimethylethoxy)carbonyl>amino>acetyl>amino>-3-methyl-1-oxobutyl>amino>-2,2-difluoro-5-<4-<2-oxo-2-(pentafluorophenoxy)ethoxy>phenyl>-N-(phenylmethyl)-L-glycero-pentonamide(158342-62-2)
• EPA Substance Registry System: <3(S),4(S)>-2,4,5-trideoxy-4-<<2-<<<<(1,1-dimethylethoxy)carbonyl>amino>acetyl>amino>-3-methyl-1-oxobutyl>amino>-2,2-difluoro-5-<4-<2-oxo-2-(pentafluorophenoxy)ethoxy>phenyl>-N-(phenylmethyl)-L-glycero-pentonamide(158342-62-2)

Safety Data

• Hazardous Substances Data: 158342-62-2(Hazardous Substances Data)

Upstream product

• 158342-61-1 <3(S),4(S)>-2,4,5-trideoxy-4-<<2-<<<<(1,1-dimethylethoxy)carbonyl>amino>acetyl>amino>-3-methyl-1-oxobutyl>amino>-2,2-difluoro-5-<4-(2-methoxy-2-oxoethoxy)phenyl>-N-(phenylmethyl)-L-glycero-pentonamide 
• 28334-73-8 (2S)-2-[[2-(tert-butoxycarbonylamino)acetyl]amino]-3-methylbutanoic acid 
• 74651-77-7 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 1963-21-9 L-glycyl-L-valine 
• 771-61-9 2,3,4,5,6-pentafluorophenol 

Downstream Products

• 158342-63-3 <9(S),12(S)>-α,α-difluoro-β-hydroxy-9-(1-methylethyl)-4,7,10-trioxo-N-(phenylmethyl)-2-oxa-5,8,11-triazabicyclo<12,2,2>octadeca-14,16,17-triene-12-propanamide 

Relevant articles and documents

Design, synthesis, and conformational analysis of a novel macrocyclic HIV- protease inhibitor

Design modifications to the lead HIV-PR inhibitor 1 (MDL 73,669, K(i) = 5 nM) have been postulated based on a computational model of the 1/HIV-PR complex. A novel macrocyclic inhibitor 8 (MDL 104,168) wherein the P1 and P3 side chain